Previous Close | 69.9 |
1-Year Change | 231.28% |
6-Months Change | 84.24% |
3-Months Change | 46.79% |
Moving Avg (50d) | 55.886 |
Moving Avg (200d) | 40.86 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 7.13B |
Beta (3-Years) | 0.83 |
Revenue Growth (ttm) | 13.18% |
Net Profit Margin (ttm) | 20.31% |
Return On Assets (ttm) | 15.38% |
EPS (ttm) | 0.81 |
PE Ratio (ttm) | 86.3 |
Dividend Yield | % |
Asset Description: | Corcept Therapeutics Incorporated |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2025-01-27 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
71.298 | 73.395 | 74.793 | 76.89 | 80.385 | 83.88 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.